RARRES2 and breast cancer: A cross sectional study involving 117 breast cancer patients by Akin et al. (51) showed that serum chemerin levels could not be used in staging of breast cancer, as there were no differences in serum chemerin levels of patients with metastatic and non-metastatic cancer.